NOVEMBER 07, 2018 Launching Test Bed for up to 10-plex assays with Simoa Sensitivity and Specificity to Advance Cancer Research Lexington, Mass. – November 7, 2018 — Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced an Early Access Program for the latest advance in Simoa Sensitivity assays... Read more
San Diego, CA, November 1, 2018 – Agena Bioscience, a global provider of molecular testing solutions, today announced the release of the Chimeric ID Panel designed to reduce the time and cost of performing chimerism analysis for bone marrow engraftment monitoring studies. The SNP-based panel is designed for research use with the MassARRAY® system and is... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announces the launch of TruSightTM Oncology 500 (TSO 500), a comprehensive pan-cancer assay designed to identify known and emerging tumor biomarkers. TruSight Oncology 500 utilizes both DNA and RNA from subject tumor samples to identify key somatic variants underlying tumor progression, such as small DNA variants, fusions, and... Read more
October 30, 2018 08:00 ET | Source: Cofactor Genomics –Enables in-house, RNA-based, solid tumor profiling with powerful, cloud-based informatics tools to inform critical clinical decisions– SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) — Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the launch of a RNA-based immune profiling kit developed for laboratories wishing to derive... Read more
Hilden, Germany, and Germantown, Maryland, October 29, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of major enhancements to QIAGEN Clinical Insight (QCI) bioinformatics solutions to deliver expanded Sample to Insight workflows for clinical next-generation sequencing (NGS). QIAGEN introduced QCI Analyze Universal for full end-to-end workflow support of all... Read more
Hilden, Germany, and Germantown, Maryland, October 29, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of three innovative Sample to Insight workflows for next-generation sequencing (NGS) research in oncology using QIAGEN’s GeneReader NGS System and other NGS platforms. QIAGEN is introducing the novel NGS workflows for clinical research in... Read more
Date: 10/29/2018 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Reader 24, a semi-automated blood typing instrument designed for medium- to small-volume laboratories. A combination centrifuge and... Read more
PDF Version Translational Research Initiative Will Use PanCancer IO 360 Panel to Identify Predictive Signatures for MGD013 SEATTLE, Oct. 29, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that MacroGenics(NASDAQ:MGNX) and NanoString have entered into a translational research agreement to identify and develop biomarkers for MacroGenics’ MGD013 program.... Read more
PDF Version Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technology, today announced the publication of the 10,000 Immunomes Project (10KIP), a seminal human immune reference standard containing mass cytometry immune cell profiles,... Read more
October 25, 2018 Updates enhance user experience, provide comprehensive characterization data, and add new models (San Diego, Calif., Oct. 25 2018) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has released MuBase 2.0. MuBase is CrownBio’s proprietary, free-to-access online database featuring... Read more